Hairy Cell Leukemia: Current Concepts

REFERENCES

• Jaffe E. S., Harris N. L., Stein H., Vardiman J. W. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoetic and Lymphoid Tissues. IARC Press, LyonFrance 2001
   Google Scholar
• Goodman G., Bethel K., Saven A. Hairy Cell Leukemia: An Update. Current Opinions in Hematology 2003; 10: 258–266
   PubMed Web of Science ®Google Scholar
• Oleske D., Golomb H. M., Farber M. D., Levy P. S. A case-control inquiry into the etiology of hairy cell leukemia. American Journal of Epidemiology 1985; 121: 675–683
   PubMed Web of Science ®Google Scholar
• Colovic M., Gralimir M., Wiernik P. Hairy cell leukemia in first cousins and review of the literature. European Journal of Haemotology 2001; 67: 185–188
   PubMed Web of Science ®Google Scholar
• Villemagne B., Bay J. O., Tournilhac O., Chaleteix C. Travade P. Two New Cases of Familial Hairy Cell Leukemia Associated with HLA Haplotypes A2, B7, Bw4, Bw6. Leukemia & Lymphoma 2005; 46: 243–245
   PubMed Web of Science ®Google Scholar
• Makower D., Marino P., Frank M., Wiernik P. H. Familiar hairy cell leukemia. Leukemia Lymphoma 1997; 29: 193–197
   Web of Science ®Google Scholar
• Casado L. F., Mouleon P., Villarrubia B., Toledo M. C., Martinez-Frejo M. C. Familial hairy cell leukemia: a HLA-linked disease or farmers linked disease?. Haematologica 1998; 83: 751–752
   PubMedGoogle Scholar
• Feuer G., Green P. L. Comparitive biology of human T-cell lymphotrophic virs type 1 (HTLV-1) and HTLV-2. Oncogene 2005; 24: 5996–6004
   PubMed Web of Science ®Google Scholar
• Haglund U., Juliusson G., Stellan B., Gahrton G. Hairy cell leukemia is characterized by clonal chromosome abnormalities clustered to specific regions. Blood 1994; 83(9)2637–45
   PubMed Web of Science ®Google Scholar
• Bouroncle B. A. Leukemic Reticuloendotheliosis (Hairy Cell Leukemia). Blood 1979; 53: 412–436
   PubMed Web of Science ®Google Scholar
• Cawley J. C., Pettitt A. R., Zuzel M. Hairy Cell Leukaemia: Biology and Management. British Journal of Haematology 1999; 106: 2
   PubMed Web of Science ®Google Scholar
• Wanko S. O., DeCasstro C. Hairy Cell Leukemia: An Elusive but Treatable Disease. The Oncologist 2006; 11: 780–789
   PubMed Web of Science ®Google Scholar
• Westbrook C. A., Golde D. W. Autoimmune Disease in Hairy-Cell Leukaemia: Clinical Syndromes and Treatment. British Journal of Haematology 1985; 349–356
   PubMed Web of Science ®Google Scholar
• Pascali E., Pezzoli A. The Clinical Spectrum of Pure Bence Jones Proteinuria: A study of 66 patients. Cancer 1988; 62: 2408–2415
   PubMed Web of Science ®Google Scholar
• Golomb H. M., Catovsky D., Golde D. W. Hairy Cell Leukemia: a clinical review based on 71 cases. Annals of Internal Medicine 1978; 89: 677–83
   PubMed Web of Science ®Google Scholar
• Saven A., Burjan C., Koziol J. A., Piro L. D. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918–26
   PubMed Web of Science ®Google Scholar
• Kampmeier P., Spielberger R., Dickstein J., Mick R., Golomb H., Vardiman J. W. Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment. Blood 1994; 83: 2931–2938
   PubMed Web of Science ®Google Scholar
• Au W. Y., Klasa R. J., Gallgher R., Le N., Gascoyne R. D., Conners J. M. Second malignancies in patients with hairy cell leukemia in British Columbia: a 20-year experience. Blood 1998; 92: 1160–1164
   PubMed Web of Science ®Google Scholar
• Hisada M., Chen Bingshu, Jaffe Elaine, Travis Lois. Second Cancer Incidence and Cause-Specific Mortality Among 3104 Patients With Hairy Cell Leukemia. A Population-Based Study. Journal of the National Cancer Institute 2007; 99(3)215–222
   PubMed Web of Science ®Google Scholar
• Matutes E., Wotherspoon A., Bro-Babapulle V., Catovsky D. The natural history and clinicopathologic features of the variant form of hairy cell leukemia. Leukemia 2001; 15: 184–186
   PubMed Web of Science ®Google Scholar
• Besa E. C. Hairy Cell Leukemia, Available from http://www.emedicine.com/MED/topic1562.htm
   Google Scholar
• Cotran R., Kumar V., Collins T. Pathologic Basis of Disease. 1999; 668–669
   Google Scholar
• Foucar K., Catovsky D. Pathology & Genetics: Tumours of Hematopoietic and Lymphoid Tissues. IARC Press, Lyon: 2001; 138–141
   Google Scholar
• Burthem J., Cawley J. C. The Bone Marrow Fibrosis of Hairy-Cell Leukemia is Caused by the Synthesis and Assembly of a Fibronectin Matrix by the Hairy Cells. Blood 1994; 83: 497–504
   PubMed Web of Science ®Google Scholar
• Naeim F. Hairy Cell Leukemia: Characteristics of the Neoplastic Cells. Human Pathology 1988; 19: 375–388
   PubMed Web of Science ®Google Scholar
• Gruber G., Schwarzmeier J. D., Shehata M., Hilgarth M., Berger R. Basic Fibroblast Growth Factor is Expressed by CD19/CD11c positive cells in Hairy Cell Leukemia. Blood 1999; 94: 1077–1085
   PubMed Web of Science ®Google Scholar
• Basso K., Arcangelo L., Tiacci E. Gene Expression Profiling of Hairy Cell Leukemia Reveals a Phenotype Related to Memory B Cells with Altered Expression of Chemokine and Adhesion Receptors. The Journal of Experimental Medicine 2004; 199(1)59–68
   PubMed Web of Science ®Google Scholar
• Hassan I. B., Hagberg H., Sundstrom C. Immunophenotype of Hairy-cell Leukemia. European Journal of Haemotology 1990; 45: 172–176
   PubMed Web of Science ®Google Scholar
• Forconi F., Sahota S. S., Raspadori D., Mockridge C. I., Lauria F., Stevenson F. K. Tumor Cells of Hairy Cell Leukemia Express Multiple Clonally Related Immunoglobulin Isotypes Via RNA Splicing. Blood 2001; 98: 1174
   PubMed Web of Science ®Google Scholar
• Goodman G. R., Bethel K. J., Saven A. Hairy Cell Leukemia; an Update. Current Opinions in Hematology 2003; 10: 258–266
   PubMed Web of Science ®Google Scholar
• Moller P., Mielke B., Moldenhauer G. Monoclonal antibody HML-1, a marker for T cells and lymphomas derived thereof, also recognizes hairy cell leukemia and some B-cell lymphomas. American Journal of Pathology 1990; 136: 509–512
   PubMed Web of Science ®Google Scholar
• Quigley M. M., Bethel K. J., Sharpe R. W., et al. CD52 expression in hairy cell leukemia. American Journal of Hematology 2003; 74(4)227–230
   PubMed Web of Science ®Google Scholar
• Hale G., Swirsky D., Waldmann H., et al. Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation. Br J Haematol. 1985; 60(1)41–48
   PubMed Web of Science ®Google Scholar
• Hale G., Xia M. Q., Tighe H. P., et al. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1998; 35(3)118–127
   Google Scholar
• Dyer M. J. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 26 1999; 5(Suppl 14)52–57
   Google Scholar
• Belov L., de la Vega O., dos Remedios C. G., et al. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Res 2001; 61(11)4483–4489
   PubMed Web of Science ®Google Scholar
• Janckila A. F. J., Cadwell E. M., Yam L. T., et al. Hairy Cell Identification by Immunohistochemistry of Tartrate-Resistant Acid Phosphatase. Blood 1995; 85: 2839–2844
   PubMed Web of Science ®Google Scholar
• Falini B., Tiacci E., Liso A., Basso K., Sabattini E., Pacini R., et al. Simple Diagnostic Assay for Hairy Cell Leukaemia by Immunocytochemical Detection of Annexin A1 (ANXA1). Lancet 2004; 363: 1869–1870
   PubMed Web of Science ®Google Scholar
• Di Bella N., Ravandi F. Purine analogue combinations for indolent lymphomas. Seminars in Hematology 2006; 43Â(Suppl. 2)S11–S21
   Google Scholar
• Van Norman A. S., Nagorney D. M., Martin J. K., Phyliky R. L., Ilstrup D. M. Splenectomy for Hairy Cell Leukemia: A Clinical Review of 63 Patients. Cancer 1986; 57: 644–648
   PubMed Web of Science ®Google Scholar
• Quesada J. R., Hersh E. M., Manning Reuben J., Keating M., Schnipper E., et al. Treatment of Hairy Cell Leukemia with Recombinant alpha-interferon. Blood 1986; 68: 493–497
   PubMed Web of Science ®Google Scholar
• Brogden R. N., Sorkin E. M. Pentostatin. A Review of its Pharmacodynamic and Pharmokinetic Properties, and Therapeutic Potential in Lymphoproliferative Disorders. Drugs 1993; 46: 652–677
   PubMed Web of Science ®Google Scholar
• Johnston J. B., Glazer R I., Pugh L., Israels L. G. The Treatment of Hairy Cell Leukemia with 2-deoxycoformycin. British Journal Haematology 1986; 63(3)525–534
   PubMed Web of Science ®Google Scholar
• Flinn I. W., Kopecky K. J., Foucar M. K., Head D., Bennett J. M., Hutchison R., et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000; 96(9)2981–2986
   PubMed Web of Science ®Google Scholar
• Catovsky D., Matutes E., Talavera J. G., O'Connor N. T., Johnson S. A., Emmett E., et al. Long-Term Results with 2'deoxycoformycin in Hairy Cell Leukemia. Leukemia and Lymphoma 1994; 14(1)109–113
   PubMed Web of Science ®Google Scholar
• Liliemark J. The Clinical Pharmacokinetics of Cladribine. Clinical Pharmacokinetics 1997; 32(2)120–131
   PubMed Web of Science ®Google Scholar
• Piro L. D., Elliso D. J., Saven A. The Scripps Clinic Experience with 2-chlorodeoxyadenosine in the Treatment of Hairy Cell Leukemia. Leukemia and Lymphoma 1994; 14(Suppl 1)121
   PubMed Web of Science ®Google Scholar
• Chadha P., Rademaker A. W., Mendiratta P., Kim B., Evanchuk D. M., Hakimian D., et al. Treatment of Hairy Cell Leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005; 106: 241–246
   PubMed Web of Science ®Google Scholar
• Robak T., Kasznicki M., Gora-Tybor J., et al. Randomized comparison of weekly administration and daily courses of cladribine in patients with hairy cell leukemia-updated results. American Society of Hematology Annual Meeting Abstracts 2004; 89: 309–313
   Google Scholar
• Else M., Ruchlemer R., Osuji N., Del Giudice I., Matutes E., Woodman A., Wotherspoon A, Catovsky D. Long remissions in hairy cell leukemia with purine analogs: A report of 219 patients with a median follow-up of 12.5 years. Cancer 2005; 104(11)2442–2448
   PubMed Web of Science ®Google Scholar
• Ribeiro P., Bouaffia F., Peaud P. Y., et al. Long term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer 1999; 85(1)65–71
   PubMed Web of Science ®Google Scholar
• Dearden C. E., Matutes E., Hilditch B. L., Swansbury G. J., Catovsky D. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. British Journal of Haematology 1999; 106(2)515–519
   PubMed Web of Science ®Google Scholar
• Zinzani P. L., Tani M., Marchi E., et al. Long term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 2004; 89: 309–313
   PubMed Web of Science ®Google Scholar
• Dearden C. E., Matutes E., Hilditch B. L., et al. Long-term follow up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. British Journal of Haematology 1999; 106: 515–519
   PubMed Web of Science ®Google Scholar
• O'Brien S., Keating M. J. Cancer Principles & Practice of Oncology Seventh Edition. Lippincott Williams & Wilkins, Philadelphia 2005; 2133–2143
   Google Scholar
• Lauria F., Benfenati D., Raspadori D., et al. Retreatment with 2-CdA of progressed HCL patients. Leuk Lymphoma 1994; 14(Suppl 1)143–145
   PubMedGoogle Scholar
• Saven A., Burian C., Koziol J. A., et al. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92(6)1918–1926
   PubMed Web of Science ®Google Scholar
• Hagberg H., Rituximab Lundholm L. A chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. British Journal of Haematology 2001; 115(3)609–611
   PubMed Web of Science ®Google Scholar
• Lauria F., Lenoci M., Annino L., et al. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 2001; 86(10)1046–1050
   PubMed Web of Science ®Google Scholar
• Nieva J., Bethel K., Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003; 102(3)810–813
   PubMed Web of Science ®Google Scholar
• Thomas D. A., O'Brien S., Bueso-Ramos C., et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003; 102(12)3906–3911, Zinzani P.L.; Ascani S.; Piccaluga P.P.; et al: Efficacy of rituximab in hairy cell leukemia treatment. J Clin Oncol. 2000 18(22), 3875–3877
   PubMed Web of Science ®Google Scholar
• Hoffman M., Auerbach L. Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine. Br J Haematol 2000; 109(4)900–901
   PubMed Web of Science ®Google Scholar
• Pollio F., Pocali B., Palmieri S., et al. Rituximab: a useful drug for a repeatedly relapsed hairy cell leukemia patient. Ann. Hematol 2002; 81(12)736–738
   PubMed Web of Science ®Google Scholar
• Thomas D. A., Ravandi F., Kantarjian H., et al. Monoclonal antibody therapy for Hairy cell leukemia. Hematol Oncol Clin North Am. 2006; 20(5)1125–36, Oct
   PubMed Web of Science ®Google Scholar
• Thomas D. A., O'Brien S., Bueso-Ramos C., Faderl S., Keating M. J., Giles F. J. Rituximab in Relapsed or Refractory Hairy Cell Leukemia. Blood 2003; 102(12)3906–3911
   PubMed Web of Science ®Google Scholar
• Hagberg H., Lundholm L. Rituximab a chimeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukemia. British Journal of Hematology 2001; 115(3)609–611
   PubMed Web of Science ®Google Scholar
• Nieva J., Bethel K., Saven A. Phase 2 study of rituximab in the treatment of cladribine failed patients with hairy cell leukemia. Blood 2005; 102(31)810–813
   Google Scholar
• Cervetti G., Galimberti S., Andreazzoli F., et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Eur. J. Haematol 2004; 73(6)412–417
   PubMed Web of Science ®Google Scholar
• Tallman M. S., Hakimian D., Kopecky K. J., et al. Minimal Residual Disease in Patients with Hairy Cell Leukemia in Complete Remission Treated with 2Chlorodeoxyadenosine or 2'-Deoxycoformycin and Prediction of Early Relapse. Clinical Cancer Research 1999; 5: 1665–1670
   PubMed Web of Science ®Google Scholar
• Ravandi F., Jorgensen J. L., O'Brien S M, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006; 107: 4658–4662
   PubMed Web of Science ®Google Scholar
• Wheaton S., Tallman M. S., Hakimian D., Peterson L. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996; 87: 1556–1560
   PubMed Web of Science ®Google Scholar
• Fietz T., Rieger K., Schmittel A., et al. Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment. Hematol J 2004; 5(5)451–452
   PubMedGoogle Scholar
• Leonard J. P., Coleman M., Ketas J. C., et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J. Clin. Oncol 2003; 21(16)3051–3059
   PubMed Web of Science ®Google Scholar
• Leonard J. P., Coleman M., Ketas J. C., et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin. Cancer Res 2004; 10(16)5327–5334
   PubMed Web of Science ®Google Scholar
• Kreitman R. J., Wilson W. H., Bergeron K., Raggio M., Stetler-Stevenson M., Fitzgerald D. J., et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant Hairy Cell Leukemia. New England Journal of Medicine 2001; 345: 241–247
   PubMed Web of Science ®Google Scholar
• Leonard J. P., Coleman M., Ketas J., et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J. Clin. Oncol. 2005; 23(22)5044–5051
   PubMed Web of Science ®Google Scholar
• Goodman G., Burian C., Koziol J., Saven A. Extended Follow-Up of Patients With Hairy Cell Leukemia After Treatment With Cladribine. Journal of Clinical Oncology 2003; Volume 21(Issue 5)891–89
   Web of Science ®Google Scholar